{
event: "article_read",
name: `Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?`,
author: ``,
tags: `Nasal Polyps`,
publication_date: ``,
interaction_type: "content"
}
Read article
Hear From An Expert On How Does Dupixent Target Underlying Type 2 Inflammation?
Over 80% of crs with nasal polyps’ patients have type 2 inflammation dupixent is the first and only biologic to inhibit il-4 and il-13 signaling in crs with nasal polyps.
.png/jcr:content/image%20(86).png)
Related articles
.png/jcr:content/2%20(3).png)
.png0/jcr:content/3%20(2).png)
Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
MAT-KW-2400275/V1/MAY2024